Please try another search
For the three months ended 31 March 2022, tella Inc revenues decreased 77% to Y5.2M. Net loss decreased 23% to Y170.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Cell Therapy Technology Development Business segment loss decrease of 21% to Y118.7M, Pharmaceuticals business segment loss decrease of 25% to Y53.6M.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 5.19 | 10.21 | 61.59 | 12.37 |
Gross Profit | -14.67 | -22.43 | -51.59 | -15.48 |
Operating Income | -171.68 | -189.98 | -371.09 | -186.56 |
Net Income | -170.37 | -170.86 | -371.79 | -185.63 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 160.94 | 326.4 | 498.49 | 850.88 |
Total Liabilities | 147.46 | 127.71 | 135.98 | 123.63 |
Total Equity | 13.48 | 198.69 | 362.51 | 727.25 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 0 Months | 6 Months |
Cash From Operating Activities | -813.63 | -418.79 | ||
Cash From Investing Activities | 95.27 | 29.43 | ||
Cash From Financing Activities | -2.73 | -1.35 | ||
Net Change in Cash | -721.09 | -390.71 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review